289 related articles for article (PubMed ID: 32768562)
1. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562
[TBL] [Abstract][Full Text] [Related]
2. Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer.
Chua CYX; Jain P; Susnjar A; Rhudy J; Folci M; Ballerini A; Gilbert A; Singh S; Bruno G; Filgueira CS; Yee C; Butler EB; Grattoni A
J Control Release; 2018 Sep; 285():23-34. PubMed ID: 30008369
[TBL] [Abstract][Full Text] [Related]
3. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer.
Liu HC; Davila Gonzalez D; Viswanath DI; Vander Pol RS; Saunders SZ; Di Trani N; Xu Y; Zheng J; Chen SH; Chua CYX; Grattoni A
Adv Sci (Weinh); 2023 Mar; 10(9):e2206873. PubMed ID: 36658712
[TBL] [Abstract][Full Text] [Related]
4. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
Knorr DA; Dahan R; Ravetch JV
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):11048-11053. PubMed ID: 30297432
[TBL] [Abstract][Full Text] [Related]
6. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1.
Park JH; Kim HY; Lee A; Seo YK; Kim IH; Park ET; Kang MS; Park SJ; Park S
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):510-520. PubMed ID: 33383126
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Van De Voort TJ; Felder MA; Yang RK; Sondel PM; Rakhmilevich AL
J Immunother; 2013 Jan; 36(1):29-40. PubMed ID: 23211623
[TBL] [Abstract][Full Text] [Related]
8. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer.
Naik A; Monjazeb AM; Decock J
Front Immunol; 2019; 10():1940. PubMed ID: 31475003
[TBL] [Abstract][Full Text] [Related]
9. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
Yokoi T; Oba T; Kajihara R; Abrams SI; Ito F
Sci Rep; 2021 Nov; 11(1):21992. PubMed ID: 34754037
[TBL] [Abstract][Full Text] [Related]
10. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
[TBL] [Abstract][Full Text] [Related]
11. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
12. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant
Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
[TBL] [Abstract][Full Text] [Related]
14. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
Chen W; Bamford RN; Edmondson EF; Waldmann TA
Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
[TBL] [Abstract][Full Text] [Related]
15. Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions.
Maulhardt H; Marin A; Hesseltine H; diZerega G
Med Oncol; 2021 Jul; 38(9):106. PubMed ID: 34331595
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
18. Radiation and Local Anti-CD40 Generate an Effective
Yasmin-Karim S; Bruck PT; Moreau M; Kunjachan S; Chen GZ; Kumar R; Grabow S; Dougan SK; Ngwa W
Front Immunol; 2018; 9():2030. PubMed ID: 30245691
[TBL] [Abstract][Full Text] [Related]
19. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
